Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 18/20 | 0.54 |
| ▸ | HTR1A | P08908 | 11/20 | 0.51 |
| ▸ | HTR1B | P28222 | 9/20 | 0.51 |
| ▸ | HTR1D | P28221 | 8/20 | 0.51 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR1E | P28566 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8725956 | 0.87 | HTR1F (0.54) | HTR1FHTR1AHTR1BHTR1DPARP1 | |
| SCHEMBL30909238 | 0.85 | HTR1F (0.46) | HTR1FHTR1AHTR1BHTR1DPARP1 | |
| SCHEMBL8724225 | 0.84 | HTR1F (0.54) | HTR1FHTR1AHTR1BHTR1DPARP1 | |
| SCHEMBL30909115 | 0.84 | HTR1F (0.54) | HTR1FHTR1AHTR1BHTR1DPARP1 | |
| SCHEMBL8385462 | 0.84 | HTR1F (0.62) | HTR1FHTR1AHTR1BHTR1DHTR2A | |
| SCHEMBL8381812 | 0.81 | HTR1F (0.63) | HTR1FHTR1AHTR1BHTR1DHTR2A | |
| SCHEMBL8724046 | 0.81 | HTR1F (0.44) | HTR1FHTR1AHTR1BHTR1DPARP1 | |
| SCHEMBL8725940 | 0.80 | HTR1F (0.51) | HTR1FHTR1AHTR1BHTR1DPARP1 | |
| SCHEMBL30908959 | 0.80 | HTR1F (0.51) | HTR1FHTR1AHTR1BHTR1DPARP1 | |
| Fumaric Acid SCHEMBL8386515 | 0.79 | HTR1F (0.59) | HTR1FHTR1AHTR1BHTR1DHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024073845-A1 | METHODS AND PHARMACOLOGICAL AGENTS FOR INCREASING EXPANSION, ENGRAFTMENT OR IMMUNE OUTPUT OF HUMAN HEMATOPOIETIC STEM CELLS IN TRANSPLANTATION AND DISEASE SETTINGS | VALORISATION HSJ, LIMITED PARTNERSHIP (CA) | 2024-04-11 | — | — | WO | disclosed |